DET dose-dependently induces apoptosis through increased levels of pro-apoptosis Bax and decreased levels of anti-apoptosis Bcl-2, with the resultant activation of caspase-9, caspase-3, cytochrome c release, and PARP cleavage in human osteosarcoma cell lines, MG-63 and U2OS (4, 8, 16, and 32 μM) [71], and human pancreatic cancer cell lines, BxPC-3 (30 and 50 μM) and CFPAC-1 (40 and 60 μM) [72]. Here, BCL2 is linked to osteosarcoma.